Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. reports recurring updates about its pharmaceutical royalty business, which owns rights to royalties from licensed pharmaceutical products and no longer conducts research and development or commercial operations. The company’s news is centered on license revenue, primarily under the Mayne License Agreement, changes in sales of licensed products, operating expense levels after its transition to a royalty-based model, and results from continuing operations.
TherapeuticsMD also provides corporate strategy updates, including disclosures about its ongoing evaluation of strategic alternatives. Its historical context includes a December 2022 shift from a women’s healthcare commercialization business to a company focused on collecting royalties from licensees.
TherapeuticsMD (TXMD) reported a solid Q2 2022 with total net revenue reaching $28.6 million, a 24% increase year-over-year. ANNOVERA revenue surged to $18.3 million, marking a 28% increase in prescriptions. Operating expenses dropped 21%, and the company achieved net income of $112.3 million, driven by a $143.4 million gain from divesting its vitaCare unit. Cash on hand decreased to $26.3 million by June 30, 2022, while $90.8 million remains under the financing agreement.
TherapeuticsMD, Inc. (NASDAQ: TXMD) will report its Q2 2022 financial results on August 15, 2022, at 8:30 a.m. ET. Executive management will host a conference call to discuss these results, accessible via audio conference line and a webcast. The live stream and a replay will be available on the TherapeuticsMD website for 30 days. The company focuses on developing healthcare products for women, addressing health issues related to family planning, reproductive health, and menopause management.
TherapeuticsMD (NASDAQ: TXMD) has secured a $15 million private investment from Rubric Capital Management to support its operating capital needs. This financing comes alongside an extension of its debt maturity date with Sixth Street Partners to September 30, 2022, with options for further extensions if additional equity of $7 million is raised.
The investment is anticipated to enable the company to continue meeting demand for its women's healthcare products while evaluating strategic options to enhance shareholder value.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has announced the anticipated termination of its Merger Agreement with EW Healthcare Partners due to the failure to acquire the required majority of shares by the tender offer deadline on July 12, 2022. Consequently, the tender offer has expired, and the Company expects the agreement to terminate following July 13, 2022. Despite this setback, TherapeuticsMD plans to maintain normal operations.
EW Healthcare Partners announced the extension of its tender offer to purchase all outstanding shares of TherapeuticsMD, Inc. (NASDAQ: TXMD) at $10.00 per share, moving the expiration date to July 12, 2022. As of July 5, 2022, approximately 29.2% of TXMD shares had been tendered. The offer is characterized as EW's best and final proposal. TherapeuticsMD previously indicated that without a successful closing of this deal, it might need to file for Chapter 11 bankruptcy protection.
EW Healthcare Partners has launched a cash tender offer for all common stock of TherapeuticsMD (TXMD) at $10.00 per share, representing a significant premium of approximately 211.8% over the 30-day average price and 367.3% over TXMD's price on May 27, 2022. The transaction is valued at around $177 million and follows a merger agreement signed on May 27, 2022. The offer will expire on July 5, 2022, unless extended. Completion is contingent upon shareholder participation and other standard conditions.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has announced a definitive merger agreement to be acquired by EW Healthcare Partners. Under the agreement, EW Healthcare will offer $10.00 per share for all outstanding TXMD shares, representing a premium of 367.3% over the stock's last closing price on May 27, 2022. The total enterprise value for TXMD is approximately $177 million. The tender offer is set to commence and will be followed by a merger, pending certain conditions. Upon completion, TXMD will become a privately held entity.
TherapeuticsMD (NASDAQ:TXMD) announced FDA approval for a supplemental New Drug Application for ANNOVERA, marking a significant milestone for the company. This approval allows for a reduction in manufacturing batch rejections and an increase in product supply, enabling an additional 7,000 rings to meet short- and long-term demand. Since its initial approval in August 2018, ANNOVERA remains the only FDA-approved, procedure-free, long-lasting reversible birth control option.
TherapeuticsMD (TXMD) reported Q1 2022 net product revenue of $19.3 million, a decrease from $19.9 million in Q1 2021. Despite ANNOVERA experiencing manufacturing challenges, prescriptions rose by 27% to 8,014. The divestiture of vitaCare for $150 million was completed in just five weeks. However, the net loss for the quarter was $49 million, or $5.69 per share. Cash on hand decreased significantly to $30.4 million from $65.1 million at the end of 2021. The company aims for improved performance moving forward.
TherapeuticsMD, Inc. (TXMD) will announce its first quarter 2022 financial results on May 16, 2022, after U.S. market close. An executive management conference call is scheduled for 4:30 p.m. ET on the same day. Investors can access the live webcast on the company's website, with a digital recording available for replay afterward. TherapeuticsMD focuses on women's healthcare, offering innovative products in family planning and menopause management. The company emphasizes its commitment to advancing women's health.